• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica

    CDMO Northway Biotech Expands in U.S.

    Global Biosciences Co. Selects ValGenesis VLMS
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica

    CDMO Northway Biotech Expands in U.S.

    Lonza to Exit Pharma Softgels and Liquid-Filled Hard Capsules
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    WDSrx Expands Warehouse Network

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Improving Product Profitability

    CDMO Northway Biotech Expands in U.S.

    Global Biosciences Co. Selects ValGenesis VLMS

    Nexelis Acquires GSK Vax Lab in Marburg

    The Future of Clinical Trials Series: Part I
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Cytovance Biologics

    Reed-Lane

    Adare Pharma Solutions

    Emergent BioSolutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Emergent BioSolutions

    Alcami

    Syngene

    Aphena Pharma Solutions

    Cytovance Biologics
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Biosimilar Manufacturing Strategies

    Five steps to competing in a post-patent expiry era.

    Biosimilar Manufacturing Strategies
    Related CONTENT
    • Bone Therapeutics, Rigenerand Ink Cell Therapy Deal
    • NovaQuest Private Equity Acquires CoreRx
    • Intravacc Completes Project for Provention Bio’s Vax Candidate
    • Biologics Development & Manufacturing
    • Cognate BioServices Announces Major Expansion
    George I’ons, Owen Mumford Pharmaceutical Services09.09.20
    As a growing number of biologics reach their patent expiry date and markets continue to open up to biosimilar manufacturers, competition for a number of drugs will continue to grow. This window of opportunity for biosimilar manufacturers could be highly profitable, with our own research estimating the biosimilar market opportunity to be $5.24 billion on average per year in the U.S. over a five-year period.1 Payors and patients could also stand to benefit from this development, as these newcomers spur competition, leading to a reduction in the cost of medications and an associated increase in access and choice. In fact, introducing biosimilars of complex biologic drugs could cut healthcare spending in the U.S. by $54 billion over the next decade.2 In the European Union, biosimilars have already generated a price discount which hovers around the 30% mark.3

    This market incentive, however, may not in itself be enough to drive biosimilar uptake. If they are to stay ahead of the curve within this increasingly competitive market, biosimilar manufacturers will need to factor in several crucial non-price aspects into their product offering. In this article, we examine some of the key factors for injectable combination products which are seen to be decisive in encouraging or discouraging switching, and allowing biosimilar manufacturers to keep ahead of the competition.

    Confidence in biosimilar products
    Given that there is often some reservation towards new products that haven’t had years of use in the field, switching patients from original biologics to biosimilars is not necessarily a straightforward procedure. Yet, the adoption of biosimilars will largely depend on the confidence of clinicians in biosimilar products. Even if similar in terms of their structure, biological activity and immunogenicity profile, biosimilars can never be an exact replica of the original product. This is likely a source of concern when swapping from one product to another.

    While independent studies4 have started to alleviate some of the initial concerns about their use, data supporting the efficacy and safety of the medicinal component of biosimilar products is still required. The FDA, for instance, requires submission of robust pharmacokinetic and dynamics study data and sometimes also supporting clinical studies in order to grant product approval and marketing authorization. In the long-term, this thorough evaluation combined with growing real-world evidence will strengthen the level of confidence in biosimilars.

    Moreover, healthcare regulators, managers and clinicians are proactively encouraging adoption where appropriate, in light of the benefits that come with biosimilar competition.

    Trust in the ancillary drug delivery device
    Beyond confidence in biosimilars as an efficient and safe biologic alternative, confidence in the drug delivery device is another essential consideration. A growing body of evidence5 shows that the design of the drug delivery device can be instrumental to facilitating a switch in either direction. This is particularly true in an age of growing self-administration by patients in a home environment or other non-traditional healthcare settings. Biosimilar manufacturers may be accustomed to designing their injectables with healthcare professionals in mind. With the rise of self-administration, however, they are now being made to adapt to meet the safety and ease-of-use concerns of a diverse pool of patients who are increasingly involved in their own medication delivery.

    In this context, the simplicity and intuitiveness of a device can function as influencing factors for patient adherence. Furthermore, patients with chronic conditions may experience gradually diminishing dexterity, making ease of use doubly critical. Devices such as auto-injectors and pre-filled safety syringe designs should ideally require minimum effort and dexterity from patients during administration, be intuitive to use and help minimize the risk of dosage errors or drug wastage. For the adoption and adherence of a biosimilar injectable to be successful, manufacturers will therefore benefit from looking beyond price reduction strategies and the efficacy of the product’s medicinal component, and working to earn patient trust in the ancillary drug delivery device that may be used to inject the therapy.

    Safety and regulations
    Compliance with safety regulations for needlestick prevention is another key factor that manufacturers will need to address, for which they are advised to partner with a device manufacturer who provides safety-engineered devices. Features that strengthen the safety of a device may encourage existing users to accept a loss of familiarity and habit. Equally, safety devices help protect healthcare workers—whether they are hospital-based or home workers—against potential infection through sharps injuries. In particular, automatic or passive needle-shielding safety mechanisms are a beneficial feature in injection devices as the patient is not required to perform any additional step after the injection procedure to protect themselves or others.

    Evidence of human factors studies
    It is vital that manufacturers carry out human factor studies to support the design of their drug delivery device. Human factors (HF) studies are fundamental to identifying and minimizing any user-associated risks that the device may present during the medication administration procedure. These tests must be comprehensive. In addition, factoring in compliance with the ISO10993 standard for biocompatibility of materials for cytotoxicity, irritation and skin sensitization is also crucial. Manufacturers must be able to demonstrate that they have thoroughly assessed and addressed all aspects of risk associated with the product in typical user environments.

    Proven manufacturability and durability
    Designing for simple manufacture and assembly are also key considerations in the device design process. While some device designs may seem more innovative, it is crucial that biosimilar manufacturers stay clear of designs which may be detrimental to the product’s manufacturability.6 In fact, usability and robustness, assembly and manufacturing risk management, supply chain reliability, environment and disposal risks, as well as post-shipping device performance must all be factored into the development process of the device, as a variety of commentators have suggested.7 Ensuring post-market monitoring is another invaluable procedure which can be used to later feed back into the design process, strengthening manufacturers’ understanding of their end-users, and demonstrating their commitment to meet patient needs.

    The ‘patent cliff’ has opened the market to biosimilar products, but manufacturers cannot rely solely on price reduction to gain a strong share in the market. To compete against other biosimilar manufacturers, close attention must be paid to drug delivery device design to encourage uptake and long-term adoption. More specifically, the rise of self-administration has rendered ease of use, comfort and convenience important factors that can significantly influence patient adherence. If they wish to gain a competitive edge within this lucrative market, biosimilar manufacturers will need to attribute special attention to every stage of device production, from patient usability and safety to manufacturability and packaging. 


    References
    1. Owen Mumford, Competitive Entry, November 2019.
    2. PharmaVoice, The Biosimilars Market, May 2019: https://www.pharmavoice.com/article/2019-05-biosimilars/
    3. See, for instance, The Oncologist, C.Nabhan, A.Valley, B.A.Feinberg, Barriers to Oncology Biosimilars Uptake in the United States, Jul 2018, The Oncologist vol.23 no.11 1261-1265.
    4. Such as American College of Rheumatology, Biosimilar Infliximab (CT-P13) is Not Inferior to Originator Infliximab: Results from a 52-Week Randomized Switch Trial in Norway, 22 Oct 2016.
    5. European Medical Journal, Filipe C. Araújo,1,2 Joao Eurico Fonseca,3,4 Joao Goncalves,5Switching to Biosimilars in Inflammatory Rheumatic Conditions: Current Knowledge, EMJ Rheumatol. 2018;5[1]:66-74; GABI Online, Alternative delivery devices for biosimilars, 1 Jun 2012.
    6. FDA, Understanding Barriers to Medical Device Quality, 2011.
    7. For instance: Pharmaceutical Online, M Song, 4 Important things to consider before designing a drug delivery device, 6 Aug 2019.
    Related Searches
    • Biosimilars
    Suggested For You
    Bone Therapeutics, Rigenerand Ink Cell Therapy Deal Bone Therapeutics, Rigenerand Ink Cell Therapy Deal
    NovaQuest Private Equity Acquires CoreRx NovaQuest Private Equity Acquires CoreRx
    Intravacc Completes Project for Provention Bio’s Vax Candidate Intravacc Completes Project for Provention Bio’s Vax Candidate
    Biologics Development & Manufacturing Biologics Development & Manufacturing
    Cognate BioServices Announces Major Expansion Cognate BioServices Announces Major Expansion
    Thermo Fisher Buys Novasep Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    Chemical Development Chemical Development
    Precision Medicine Group Acquires Project Farma Precision Medicine Group Acquires Project Farma
    Charles River Partners with JADE Charles River Partners with JADE
    Cytiva Delivers Modular Biologics Factory to Lonza Cytiva Delivers Modular Biologics Factory to Lonza
    Fujifilm, CABIM Get $76M Funding for Mfg. and Innovation Center Fujifilm, CABIM Get $76M Funding for Mfg. and Innovation Center
    LSNE Expands Fill Finish and Lyophilization Ops LSNE Expands Fill Finish and Lyophilization Ops
    Pharmaceutical and Biotherapeutic Development and Testing Pharmaceutical and Biotherapeutic Development and Testing
    RheinCell Therapeutics Achieves GMP Certification RheinCell Therapeutics Achieves GMP Certification
    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Related Features

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20

    • Biosimilars
      The U.S. Biosimilars Market: Shaking the “Laggard” Label

      The U.S. Biosimilars Market: Shaking the “Laggard” Label

      Biosimilar uptake set to reshape the U.S. market
      Katya Svoboda and Bob Swann, ICON 05.05.20

    • Biologics, Proteins, Vaccines | Biosimilars
      Biopharma Over 20 Years

      Biopharma Over 20 Years

      A look at the key trends that have impacted the biopharma industry over the years.
      K. John Morrow, Jr. and Eric S. Langer, BioPlan Associates 11.20.19


    • Biologics, Proteins, Vaccines | Biosimilars
      Are Biotech Companies Strong Investments?

      Are Biotech Companies Strong Investments?

      Biotech capital raised via IPO has increased dramatically over the past couple of years.
      Jason Monteleone , CEO, Clinipace 05.07.19

    • Biosimilars
      Biosimilar  Market Trends

      Biosimilar Market Trends

      2017 was a record year for biosimilar approvals.
      Fiona Greer and Bruno Speder, SGS 09.11.18

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Haste Makes Waste

      Haste Makes Waste

      When to sprint and when to breathe in the race from lab to clinic.
      Christian Cattaruzza, MilliporeSigma 09.11.18


    • Biologics, Proteins, Vaccines | Biosimilars
      Biopharma Manufacturing Markets

      Biopharma Manufacturing Markets

      Biomanufacturing contract services and supplies markets continue to expand
      Ronald A. Rader and Eric S. Langer, BioPlan Associates 05.08.18

    • Biologics, Proteins, Vaccines | Biosimilars
      Contract BioManufacturing in China: Creating a New Segment

      Contract BioManufacturing in China: Creating a New Segment

      An up-close look at China’s growing market for CMO services.
      Vicky Qing Xia and Leo Cai Yang, BioPlan Associates 04.10.18

    • Biologics, Proteins, Vaccines | Biosimilars | cGMP Manufacture
      Biopharmaceutical Contract Manufacturing Market

      Biopharmaceutical Contract Manufacturing Market

      The market continues to grow, projected to exceed $4 billion in 2017
      William Downey, President, HighTech Business Decisions 06.06.17


    • Aseptic Processing | Biosimilars | Drug Delivery | Logistics | Supply Chain
      Improving Packaging Processes to Meet Regulatory and Patient Needs

      Improving Packaging Processes to Meet Regulatory and Patient Needs

      The rise of advanced automation and packaging technologies
      06.02.16

    • Biosimilars | Drug Delivery | Injectables | Parenterals | Serialization | Supply Chain | Vials
      Contract Packaging Market Trends

      Contract Packaging Market Trends

      Contract packagers talk about hot growth areas and the looming 2017 DSCSA deadline
      Tim Wright, Editor 06.02.16

    • Biosimilars | Chemistry | Process Development | Supply Chain
      Biopharma CMO Market Trends

      Biopharma CMO Market Trends

      Continued strong growth in biopharma industry is being driven by biosimilars
      Tim Wright, Editor 06.02.16


    • Biosimilars | Clinical Trials | Formulation Development
      Critical Steps for Biosimilar Assessment

      Critical Steps for Biosimilar Assessment

      Establishing “finger-print like” biosimilarity prior to the clinic
      Fiona Greer, SGS 05.05.16

    • Biosimilars | Clinical Trials | Drug Development
      The Evolving Landscape of Drug Development in China

      The Evolving Landscape of Drug Development in China

      Innovation agenda includes expanded use of biosimulation
      Christine Yuying Gao and Ellen Leinfuss, Certara 05.05.16

    • Biosimilars | Clinical Trials | Process Development
      Biosimilars Outsourcing and Capacity

      Biosimilars Outsourcing and Capacity

      CMOs to play important but uncertain role in biosimilars manufacturing
      Ronald A. Rader and Eric S. Langer, BioPlan Associates 05.05.16

    Trending
    • The Future Of Clinical Trials Series: Part I
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • Lonza To Exit Pharma Softgels And Liquid-Filled Hard Capsules
    • Nexelis Acquires GSK Vax Lab In Marburg
    • CDMO Northway Biotech Expands In U.S.
    Breaking News
    • WDSrx Expands Warehouse Network
    • Piramal Inks Clinical Supply Deal with Theratechnologies
    • Recipharm Signs Manufacturing Deal with Enzymatica
    • CDMO Northway Biotech Expands in U.S.
    • Global Biosciences Co. Selects ValGenesis VLMS
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    NIH Study Compares Low-Fat, Plant-based to Low-Carb, Animal-Based Diet
    Gadot Positions Mineral Line for Vegan Market
    Nutritfy India to Launch Global Broadcast Channel Covering Nutrition
    Coatings World

    Latest Breaking News From Coatings World

    IGL Coatings Launches Graphene Reinforced Dual System Ceramic Coating
    Miller Paint Declares Simple Serenity its 2021 Color of the Year
    TAUBMANS Paint by PPG Releases ‘Chromatic Joy’ Palettes
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    TPI Partners with Zeiss
    PPE Moves into New Manufacturing Facility
    Neurent Medical Closes $25 Million Series B Financing
    Contract Pharma

    Latest Breaking News From Contract Pharma

    WDSrx Expands Warehouse Network
    Piramal Inks Clinical Supply Deal with Theratechnologies
    Recipharm Signs Manufacturing Deal with Enzymatica
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Lageen Tubes Launches Mono-Material PE Tube Solutions
    Jason Jones Loses Battle with Covid-19
    Weleda Celebrates 100 Years By 'Opening' Its Gardens
    Happi

    Latest Breaking News From Happi

    NY's 1,4-Dioxane Law May Impact Concentrated Cleaners
    Sabinsa's Top Scientist Addresses US FDA
    Ipsy Adds New Personal Care Brand
    Ink World

    Latest Breaking News From Ink World

    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    THIMM Group Installs 1st Koenig & Bauer CorruFLEX
    Cowan Graphics Adds Fujifilm Inca OnsetX3 HS
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Lemu Group engineers mask-making machine
    Niagara Label upgrades with Nilpeter flexo press
    Soma partners with Moore & Moore in US
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Lemu Group Engineers Mask-Making Machine
    Armbrust American Adds Meltblown Manufacturing
    P&G Reports 8% Sales Increase
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Siemens Healthineers’ DR Systems Cleared by FDA
    Former Medtronic Exec Appointed Zimmer Biomet's Chief Transformation Officer
    SeaSpine Launches Regatta Lateral Plates
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Graphene Flagship Launches Redesigned Website

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login